Key Highlights

  • TempraMed Technologies (CN:VIVI:CNX) fell 1.49% to a quoted CAD 0.33, with a market Capitalization of CAD 26.52 million and a 14-period RSI of 24.98.
  • TempraMed sells thermal insulation devices, including VIVI Cap and VIVI Med, and has distribution relationships in Israel and the United States.
  • In September 2026, the company reported record July sales and an expanded Latin American distribution agreement, and on September 30 it announced the closing of a private placement.
  • No company-specific catalyst was identified in the disclosures reviewed. The disclosures reviewed do not explain the decline, and sales updates, distribution rollout and financing use are the main items to monitor.

Introduction

TempraMed Technologies Ltd. (CN:VIVI:CNX) is a medical technology company listed on the Canadian Securities Exchange that makes battery-free thermal insulation devices for temperature-sensitive medications such as insulin. Its shares fell 1.49% to CAD 0.33 on November 3, 2026, with a market capitalization of CAD 26.52 million and a 14-period RSI of 24.98. The question for investors is how a decline of 1.49% relates to a company that reported record July sales in September and closed a private Placement on September 30.

Catalyst and Latest Updates

TempraMed makes patented thermal insulation products that protect temperature-sensitive medications without batteries or external power. Its range includes VIVI Cap, VIVI Cap Smart, VIVI Epi and VIVI Med. On February 10, 2026, it announced a national rollout through Super-Pharm, a large pharmacy chain in Israel, and it also announced a distribution agreement with CenterWell Pharmacy, the pharmacy services Brand of Humana.

In September 2026, the company reported record July sales and a strong August, stating that sales for the year to date had already exceeded its full-year 2025 revenue. It then expanded its Latin American distribution agreement, announced an additional commercial order and a private placement, and on September 30 announced that the placement had closed, with proceeds directed to inventory, product development, global sales and marketing, and working capital. The disclosures reviewed did not say whether insiders took part.

No company-specific catalyst was identified in the disclosures reviewed. The disclosures reviewed identify no announcement on November 3, so the move cannot be tied to a specific development.

Volume, Data and Context

A price of CAD 0.33 and a decline of 1.49% describe a small move.

The market capitalization of CAD 26.52 million is the total value the market places on the outstanding shares at the quoted price. At CAD 26.52 million, TempraMed is a micro-cap company whose value reflects its product growth and distribution expansion more than a long Earnings record. Market Value does not show whether shares are expensive or inexpensive.

The 14-period RSI of 24.98 indicates strongly negative recent momentum. RSI, or Relative Strength Index, compares the size of recent gains with the size of recent losses, and readings at the low end of its scale are conventionally described as oversold. The timeframe of the indicator was not specified. A low reading describes how the price has behaved; it does not explain the weakness, and it does not signal that a Reversal is coming. The session’s decline of 1.49% is consistent with that momentum but does not establish its cause.

Taken together, the figures describe a micro-cap medical products company with improving sales disclosures, whose shares show very weak momentum and a small decline on the session, with no confirmed company-specific cause.

Risks and What to Watch

Financing and dilution risk are central. The September placement included convertible debentures and units with warrants, and conversion or exercise would add to the share count.

Commercial execution risk follows. Distribution agreements describe access to channels, but sales depend on pharmacy and patient adoption.

Concentration risk applies, as growth relies on a small number of products and distributors.

Liquidity is limited on the Canadian Securities Exchange, so prices can move sharply on small volumes.

Investors should watch for the next sales update, results for the period including the September placement, distribution rollout in the United States and Latin America, and the company’s filings.

Outlook

The company says it intends to expand into new markets and into higher-value injectable medications through VIVI Med. These are company statements rather than guarantees, and the price, market capitalization and RSI do not measure progress.

Where Things Stand

TempraMed Technologies (CSE:VIVI) fell 1.49% to a quoted CAD 0.33, with a market capitalization of CAD 26.52 million and an RSI of 24.98. What is known is that momentum has been strongly negative, that the company reported record July sales and that it closed a private placement on September 30. What remains uncertain is why the shares fell, since no company-specific catalyst was identified in the disclosures reviewed. The next sales update and financial results would give the clearest evidence. The figures should be treated as a snapshot, since the time of the data was not provided.